

Gavin P Dunn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2061046/publications.pdf>

Version: 2024-02-01

101
papers

20,619
citations

100601

38
h-index

49824

91
g-index

103
all docs

103
docs citations

103
times ranked

31642
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Therapeutic applications of the cancer immunoeediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77. | 4.3 | 29 |
| 2 | Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602. | 3.2 | 67 |
| 3 | Applied cancer immunogenomics in glioblastoma. , 2022, , 19-38. | | 0 |
| 4 | Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis. <i>Cancer Discovery</i> , 2022, 12, 154-171. | 7.7 | 34 |
| 5 | Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA. <i>Theranostics</i> , 2022, 12, 362-378. | 4.6 | 21 |
| 6 | Is There a Role for Immunotherapy in Central Nervous System Cancers?. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 237-252. | 0.9 | 5 |
| 7 | Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac002. | 0.4 | 3 |
| 8 | Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 2567-2578. | 3.2 | 20 |
| 9 | Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response. <i>Genome Medicine</i> , 2022, 14, 49. | 3.6 | 37 |
| 10 | Considerations for personalized neoantigen vaccination in Malignant glioma. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114312. | 6.6 | 13 |
| 11 | Using Histopathology to Assess the Reliability of Intraoperative Magnetic Resonance Imaging in Guiding Additional Brain Tumor Resection: A Multicenter Study. <i>Neurosurgery</i> , 2021, 88, E49-E59. | 0.6 | 8 |
| 12 | A review of glioblastoma immunotherapy. <i>Journal of Neuro-Oncology</i> , 2021, 151, 41-53. | 1.4 | 159 |
| 13 | Photosensitivity Reaction From Operating Room Lights After Oral Administration of 5-Aminolevulinic Acid for Fluorescence-Guided Resection of a Malignant Glioma. <i>Cureus</i> , 2021, 13, e13442. | 0.2 | 0 |
| 14 | Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 2326-2339. | 3.2 | 16 |
| 15 | 39607 Mapping the Draining Lymph Nodes in Central Nervous System Malignancies. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 37-37. | 0.3 | 0 |
| 16 | Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. <i>Neurosurgery</i> , 2021, 89, 129-132. | 0.6 | 5 |
| 17 | Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. <i>Genome Medicine</i> , 2021, 13, 56. | 3.6 | 34 |
| 18 | Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2070-TPS2070. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-17, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data.. Journal of Clinical Oncology, 2021, 39, 2040-2040. | 0.8 | 2 |
| 20 | Personalized DNA neoantigen vaccine in combination with plasmid IL-12 for the treatment of a patient with anaplastic astrocytoma.. Journal of Clinical Oncology, 2021, 39, e14561-e14561. | 0.8 | 0 |
| 21 | Internal dose escalation associated with increased local control for melanoma brain metastases treated with stereotactic radiosurgery. Journal of Neurosurgery, 2021, 135, 855-861. | 0.9 | 4 |
| 22 | Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary, 2021, 24, 359-373. | 1.6 | 12 |
| 23 | Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms. Biomarker Insights, 2021, 16, 117727192110066. | 1.0 | 6 |
| 24 | Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma. Neuro-Oncology Advances, 2021, 3, vdab081. | 0.4 | 1 |
| 25 | Unique challenges for glioblastoma immunotherapy” discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375. | 0.6 | 59 |
| 26 | Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in glioblastoma. Nature Communications, 2021, 12, 6321. | 5.8 | 16 |
| 27 | Serving on the Navy's Hospital Ships During the Response to COVID-19: Perspective from Two Deployed Missouri Physicians. Missouri Medicine, 2021, 118, 110-112. | 0.3 | 0 |
| 28 | 777”Personalized DNA vaccine in combination with plasmid encoded IL-12 for the treatment of a patient with anaplastic astrocytoma. , 2021, 9, A812-A812. | | 0 |
| 29 | Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa126. | 0.4 | 27 |
| 30 | Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus”Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research, 2020, 26, 5140-5152. | 3.2 | 163 |
| 31 | Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707. | 0.6 | 1 |
| 32 | Cancers from Novel <i>Pole</i>-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. Cancer Research, 2020, 80, 5606-5618. | 0.4 | 14 |
| 33 | GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Scientific Reports, 2020, 10, 9027. | 1.6 | 20 |
| 34 | Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine. Neuro-Oncology, 2020, 22, 1276-1288. | 0.6 | 51 |
| 35 | TERT, a promoter of CNS malignancies. Neuro-Oncology Advances, 2020, 2, vdaa025. | 0.4 | 22 |
| 36 | Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro-Oncology, 2020, 22, 1425-1438. | 0.6 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772. | 0.6 | 131 |
| 38 | IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii363-iii363. | 0.6 | 1 |
| 39 | Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. <i>Journal of Neurosurgery</i> , 2020, , 1-10. | 0.9 | 20 |
| 40 | An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments. <i>Missouri Medicine</i> , 2020, 117, 45-49. | 0.3 | 1 |
| 41 | SURG-12. PREDICTORS OF SURVIVAL AND UTILITY OF INTRAOPERATIVE MRI FOR RESECTION OF GRADE II ASTROCYTOMAS AND OLIGODENDROGLIOMAS: A MULTICENTER ANALYSIS. <i>Neuro-Oncology</i> , 2020, 22, ii205-ii206. | 0.6 | 0 |
| 42 | IMMU-53. CHARACTERIZATION OF THE GENOMIC AND IMMUNOLOGICAL DIVERSITY OF MALIGNANT BRAIN TUMORS THROUGH MULTI-SECTOR ANALYSIS. <i>Neuro-Oncology</i> , 2020, 22, ii116-ii116. | 0.6 | 0 |
| 43 | IMMU-26. UNRAVELING ANTIGEN PRESENTATION IN CENTRAL NERVOUS SYSTEM ANTI-TUMOR IMMUNITY. <i>Neuro-Oncology</i> , 2020, 22, ii110-ii110. | 0.6 | 0 |
| 44 | Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. <i>Oncotarget</i> , 2019, 8, e1561106. | 2.1 | 50 |
| 45 | Characterization and validation of an intrafraction motion management system for masked-based radiosurgery. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 21-26. | 0.8 | 13 |
| 46 | IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, ii96-ii97. | 0.6 | 0 |
| 47 | Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2032-2032. | 0.8 | 33 |
| 48 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753. | 0.8 | 13 |
| 49 | Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002444. | 0.5 | 16 |
| 50 | T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 4175-4186. | 3.2 | 402 |
| 51 | Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress. <i>Cell Reports</i> , 2018, 22, 512-522. | 2.9 | 74 |
| 52 | Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 472-483. | 0.6 | 42 |
| 53 | Focused Ultrasound-enabled Brain Tumor Liquid Biopsy. <i>Scientific Reports</i> , 2018, 8, 6553. | 1.6 | 55 |
| 54 | Direct puncture Onyx embolization of a large calvarial metastasis with intracranial extension: Case report. <i>Interventional Neuroradiology</i> , 2018, 24, 220-224. | 0.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | IMMU-05. LATE EFFECTS OF INTRACRANIAL RADIATION INDUCES RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE THERAPY THAT IS PARTIALLY REVERSIBLE WITH CSF-1R INHIBITION. <i>Neuro-Oncology</i> , 2018, 20, vi122-vi122. | 0.6 | 0 |
| 56 | A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. <i>Nature Genetics</i> , 2018, 50, 1735-1743. | 9.4 | 62 |
| 57 | Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. <i>Radiotherapy and Oncology</i> , 2018, 128, 266-273. | 0.3 | 48 |
| 58 | Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 4109-4119. | 0.8 | 34 |
| 59 | Applied Cancer Immunogenomics. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 125-130. | 1.0 | 16 |
| 60 | Genomic landscape of high-grade meningiomas. <i>Npj Genomic Medicine</i> , 2017, 2, . | 1.7 | 130 |
| 61 | Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10. | 13.5 | 596 |
| 62 | Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 71, 169-176. | 0.8 | 16 |
| 63 | Targeting Neoantigens in Glioblastoma. <i>Neurosurgery</i> , 2017, 64, 165-176. | 0.6 | 24 |
| 64 | Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. <i>Cell Communication and Signaling</i> , 2017, 15, 34. | 2.7 | 21 |
| 65 | Genomic profile of human meningioma cell lines. <i>PLoS ONE</i> , 2017, 12, e0178322. | 1.1 | 44 |
| 66 | Management of intracranial melanomas in the era of precision medicine. <i>Oncotarget</i> , 2017, 8, 89326-89347. | 0.8 | 16 |
| 67 | Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576. | 0.8 | 100 |
| 68 | Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline <i>POLE</i> Deficiency Treated with Checkpoint Blockade Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1230-1236. | 7.7 | 242 |
| 69 | Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. <i>Cancer Immunology Research</i> , 2016, 4, 1007-1015. | 1.6 | 84 |
| 70 | Genomic landscape of intracranial meningiomas. <i>Journal of Neurosurgery</i> , 2016, 125, 525-535. | 0.9 | 104 |
| 71 | High incidence of TERT mutation in brain tumor cell lines. <i>Brain Tumor Pathology</i> , 2016, 33, 222-227. | 1.1 | 26 |
| 72 | Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2080-TPS2080. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS6110-TPS6110. | 0.8 | 5 |
| 74 | Principles of immunology and its nuances in the central nervous system: Fig. 1.. Neuro-Oncology, 2015, 17, vii3-vii8. | 0.6 | 28 |
| 75 | A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. Cell Reports, 2015, 11, 1809-1821. | 2.9 | 82 |
| 76 | Surgical Revascularization in North American Adults with Moyamoya Phenomenon: Long-Term Angiographic Follow-up. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1597-1608. | 0.7 | 26 |
| 77 | Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1000-1007. | 0.4 | 80 |
| 78 | The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Molecular Cancer Research, 2015, 13, 502-509. | 1.5 | 26 |
| 79 | Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2015, 33, TPS2077-TPS2077. | 0.8 | 2 |
| 80 | Emerging Insights into Barriers to Effective Brain Tumor Therapeutics. Frontiers in Oncology, 2014, 4, 126. | 1.3 | 127 |
| 81 | In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1102-1107. | 3.3 | 42 |
| 82 | Three-dimensional brain surface visualization for epilepsy surgery of focal cortical dysplasia. Journal of Clinical Neuroscience, 2014, 21, 1230-1232. | 0.8 | 2 |
| 83 | A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease. Clinical Cancer Research, 2014, 20, 2873-2884. | 3.2 | 84 |
| 84 | The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477. | 13.5 | 3,979 |
| 85 | Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis Type 1. Journal of Neurosurgery, 2013, 118, 142-148. | 0.9 | 65 |
| 86 | From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurgical Focus, 2013, 34, E2. | 1.0 | 59 |
| 87 | Cancer Immunoediting in Malignant Glioma. Neurosurgery, 2012, 71, 201-223. | 0.6 | 79 |
| 88 | Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784. | 2.7 | 463 |
| 89 | Dual Ipsilateral Craniotomies Through a Single Incision for the Surgical Management of Multiple Intracranial Aneurysms. World Neurosurgery, 2012, 77, 502-506. | 0.7 | 8 |
| 90 | Surgical Treatment of a Large Fusiform Distal Anterior Cerebral Artery Aneurysm With In Situ End-to-Side A3A3 Bypass Graft and Aneurysm Trapping: Case Report and Review of the Literature. Neurosurgery, 2011, 68, E587-E591. | 0.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia. <i>Head and Neck</i> , 2008, 30, 267-272. | 0.9 | 9 |
| 92 | Mycotic Pseudoaneurysm of the Internal Maxillary Artery. <i>JAMA Otolaryngology</i> , 2007, 133, 402. | 1.5 | 6 |
| 93 | Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. <i>Cancer Immunity</i> , 2007, 7, 12. | 3.2 | 102 |
| 94 | Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity. <i>Advances in Immunology</i> , 2006, 90, 1-50. | 1.1 | 689 |
| 95 | Interferons, immunity and cancer immunoediting. <i>Nature Reviews Immunology</i> , 2006, 6, 836-848. | 10.6 | 1,312 |
| 96 | IFN Unresponsiveness in LNCaP Cells Due to the Lack of <i>JAK1</i> Gene Expression. <i>Cancer Research</i> , 2005, 65, 3447-3453. | 0.4 | 161 |
| 97 | Interferon- β and Cancer Immunoediting. <i>Immunologic Research</i> , 2005, 32, 231-246. | 1.3 | 123 |
| 98 | A critical function for type I interferons in cancer immunoediting. <i>Nature Immunology</i> , 2005, 6, 722-729. | 7.0 | 516 |
| 99 | The Three Es of Cancer Immunoediting. <i>Annual Review of Immunology</i> , 2004, 22, 329-360. | 9.5 | 2,422 |
| 100 | The Immunobiology of Cancer Immunosurveillance and Immunoediting. <i>Immunity</i> , 2004, 21, 137-148. | 6.6 | 2,486 |
| 101 | Cancer immunoediting: from immunosurveillance to tumor escape. <i>Nature Immunology</i> , 2002, 3, 991-998. | 7.0 | 4,290 |